Stay updated on Rituximab in Eosinophilic Granulomatosis Clinical Trial

Sign up to get notified when there's something new on the Rituximab in Eosinophilic Granulomatosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Rituximab in Eosinophilic Granulomatosis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-13T22:35:28.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase III clinical trial comparing rituximab-based regimen with conventional therapy for inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). This change reflects the ongoing evaluation of rituximab as a potential remission-induction treatment for EGPA, aiming to improve outcomes for patients with this complex inflammatory disease.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:56.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as general health condition and prior treatments. Additionally, the inclusion criteria now specify that patients must have a diagnosis of EGPA, be 18 years or older, and have either newly-diagnosed or relapsing disease.
    Difference
    23%
    Check dated 2024-05-22T20:59:54.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T21:51:29.000Z thumbnail image

Stay in the know with updates to Rituximab in Eosinophilic Granulomatosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Rituximab in Eosinophilic Granulomatosis Clinical Trial page.